MP59-19 UPDATE OF TRUCE-02: AN OPEN LABEL, SINGLE-ARM, PHASE 2 STUDY OF TILELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR HIGH-RISK NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (HR-NMIBC) WHICH IS NOT COMPLETELY RESECTABLE. (May 2022) - Hu, Hailong; Niu, Yuanjie; Wang, Haitao; Shen, Chong; Da, La; Zhao, Gangjian; Wang, Lili; Wu, Zhouliang; Zhang, Zhe; Li, Zhi; Jiang, Zhan; Zhan, Xuejian; et al.